Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
Portfolio Transition | Explore BMY's strategic shift from legacy products to innovative therapies, balancing the decline of Revlimid with promising launches like Cobenfy and OPDIVO Qvantig |
Pipeline Potential | Delve into BMY's cell therapy advancements, including GPRC5D CAR T for multiple myeloma and CD19 NEX-T for autoimmune diseases, showcasing future growth prospects |
Financial Outlook | Analyst projections for BMY vary, with FY2025 revenue estimates between $45.6B-$48.3B and EPS forecasts of $6.65-$7.35, reflecting transition uncertainties |
Market Positioning | Learn how BMY navigates fierce competition in oncology, leveraging its strengths while expanding into new therapeutic areas to secure its pharmaceutical industry standing |
Metrics to compare | BMY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBMYPeersSector | |
---|---|---|---|---|
P/E Ratio | 19.0x | 16.2x | −0.5x | |
PEG Ratio | 0.10 | −0.10 | 0.00 | |
Price/Book | 5.9x | 1.6x | 2.6x | |
Price / LTM Sales | 2.2x | 2.9x | 3.1x | |
Upside (Analyst Target) | 9.5% | 362.4% | 48.3% | |
Fair Value Upside | Unlock | 30.4% | 7.6% | Unlock |